This clearly spells out our future estimated revenues.......
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAFTM kits provide proof of concept for the RECAF technology. BOCX has patented and proprietary technology that is leading the way in early cancer detection.
BOCX is currently developing and commercializing cancer diagnostic products based upon their breakthrough RECAFTM cancer marker technology.
A vaccine based on BOCX's proprietary RECAFTM technology that would protect against most types of cancer has a $2B market potential in U.S. alone.
Radioisotope imaging of RECAFTM positive cancer cells can be obtained with standard hospital equipment. Projected as a $1B U.S. market share for BOCX.
$ 2 Billion Dollar market targeted for BOCX's single serum test for the diagnosis of numerous types of cancer. To be launched under the name Serum-RECAFTM. $3 Billion Dollar market share is seen as realistic as BOCX joins the Antibody Therapy arena with very favorable results from preliminary studies based on BOCX's RECAFTM technology. BOCX targets growing market for minimizing or eliminating side effects of cancer chemotherapy, utilizing its RECAFTM antibodies for drug and radioisotope delivery. BOCX is seen as a prime-licensing candidate based on the multitude of clinical uses of BOCX's proprietary RECAF TMtechnology. BOCX has assembled a team of renowned individual scientists and experts under the direction of Dr. Phillip Gold, the most eminent investigator in the cancer marker field. Investigators at BOCX have demonstrated that leukemia can be diagnosed and monitored utilizing BOCX's RECAFTM staining technology. By cleansing patients' bone marrow of cancer cells, need for bone marrow transplants might be eliminated.
BOCX's Histo-RECAFTM, a special cancer detection kit for tissues, has been cleared for sale by the FDA for U.S. markets, with an early projected market potential of $200 million. Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.
